"An investigational long-acting form of recombinant human growth hormone (rhGH) given twice a month has achieved efficacy and safety at 2 years, new data show.
The novel long-acting recombinant human growth hormone fusion protein somav"...
Since CORTROSYN™ (cosyntropin) for Injection is intended for diag-nostic and not therapeutic use, adverse reactions other than a rare hypersensitivity reaction are not anticipated. A rare hypersensitivity reaction usually associated with a pre-existing allergic disease and/or a previous reaction to natural ACTH is possible. Symptoms may include slight whealing with splotchy erythema at the injection site. There have been rare reports of anaphylactic reaction. The following adverse reactions have been reported in patients after the admin-istration of CORTROSYN™ (cosyntropin) and the association has been neither confirmed nor refuted:
Read the Cortrosyn (cosyntropin) Side Effects Center for a complete guide to possible side effects
Last reviewed on RxList: 9/9/2008
Additional Cortrosyn Information
- Cortrosyn Drug Interactions Center: cosyntropin inj
- Cortrosyn Side Effects Center
- Cortrosyn Overview including Precautions
- Cortrosyn FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.